Deletion of the Hck binding region in the IL-6 receptor
AssigneeGSF-Forschungszentrum fur Umwelt und Gesundheit GmbH
InventorsMichael Schaeffer, Michaela Schneiderbauer, Sascha Weidler, Michael Hallek
Life of this patent
Estimating the term…
Abstract
The present invention describes a means for the treatment of multiple myeloma. Deletion mutants of the gp130 protein of the IL-3 receptor are presented which inhibit the binding of Hck tyrosine kinase and the growth of tumor cells, particularly of myeloma cells.
Claims2
Human IL-6 receptor protein having a deletion in the gp130 chain of the region corresponding to amino acids 771-811 of wild-type gp130 or of portions of said region so that the specific binding of Hck tyrosine kinase to gp130 is abolished.
Human gp130 protein having a deletion of the region corresponding to amino acids 771-811 of wild-type gp130 or of portions of said region so that the specific binding of Hck tyrosine kinase to gp130 is abolished.
Dependencies are inferred from the claim text.